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Background
Unintended pregnancy in adolescents, which was reported 
to be about 50% of all adolescent pregnancies, can be 
prevented by variety of types of contraceptives. Previous 
research showed that the progestin-based contraceptive, 
Depot medroxyprogesterone acetate (DMPA), has been 
associated with enhanced HIV acquisition in adult 
women.1,2,3 However, the impact have not been assessed 
in adolescent girls, a population bearing a 
disproportionate burden of both the HIV epidemic and 
often-unintended pregnancies. Currently, the data on 
immunological consequences of continued usage of 
progestin-based contraceptives on genital tract of 
adolescent girls in the United States is insufficient. 
Therefore, the objective of this study was to examine the 
genital inflammatory immune biomarkers associated with 
HIV acquisition following usage of three types of 
progestin-based contraceptives, levonorgestrel 
intrauterine device (LNG-IUD), subdermal etonogestrel
(ETNG), and injectable DMPA, in adolescent girls.
Methods
Following IRB approval, 59 sexually active, HIV-negative
adolescent girls (ages 15-19) were recruited from
Children’s National Medical Center and Medstar
Washington Hospital Center in Washington, DC from 2017
to 2019. After contraceptive counseling, participants self-
selected into different study arms: Control (condoms
only), combined oral contraceptive pills (COC), LNG-IUD,
ETNG and DMPA groups, which included 11, 14, 15, 11,
and 9 participants per group at baseline, respectively.
Vaginal swabs were collected at baseline prior to
contraceptive use, and again at a 3-month follow-up visit.
Vaginal secretions were tested for pro-inflammatory
immune mediators, IL-6, TNF-α, IL-1α, IL-1β, IP-10, MIP-
1α using ELISA. Biomarker data were then analyzed using
Wilcoxon Rank Sum Test and Kruskal Wallis Test (SAS 9.4)
to evaluate differences between visits across treatment
groups. The comparison of Log-transformed biomarkers
were analyzed by Graphpad Prism.
Results
Thirty-four participants provided both baseline and follow-up samples: 6
participants for control (condom only), 7 for COC, 9 for LNG-IUD, 7 for ETNG
and 5 for DMPA. Participants differed by race and age distribution among
contraceptive groups (Table 1). Statistically significant differences in median
biomarker levels between Baseline and follow-up visit were only observed
for TNF-α, decreasing from the baseline visit compared to the follow-up
visit, in the COC arm (Figure 1, p = 0.046).
Conclusions
The study indicated that usage of progestin-based contraceptives may
not play a significant role in increasing inflammation when compared to
contenders. Consequently, the study suggests that progestin-based
contraceptives do not impact inflammatory genital immune biomarkers
associated with HIV susceptibility. However, we demonstrate the need
of future research studies in this with larger sample size and longer
follow-up period to evaluate safe and effective contraceptives in
adolescent girls to prevent unintended pregnancies and HIV
transmission.References
1. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS 2016;30:2665–83
2. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Lancet 2019; 394: 302.
3. Curtis KM, Hannaford PC, Rodriquez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal contraception and HIV acquisition among women: an updated systematic review. BMJ Sex Reprod Health 2020 46: 8-16.
Research supported by: R21 HD089836-01A1(Ghosh and Gomez-Lobo)
Table 1: Demographic Information Figure 1: Comparison of Log-Transformed Median Biomarker Levels by Visit and 
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